Literature DB >> 8630024

Coexpression of flt-1, flt-4 and KDR in freshly isolated and cultured human endothelial cells.

P W Hewett1, J C Murray.   

Abstract

Vascular endothelial cell growth factors (VEGF) are key modulators of endothelial cell growth and function. The class III receptor tyrosine kinases KDR and Flt-1 are high affinity receptors for VEGF, while Flt-4 is a receptor for the recently identified VEGF-C. We have examined the expression of flt-1, flt-4 and KDR in human microvascular and large vessel endothelial cells and in a variety of other cell types in vitro. Endothelial cells proliferated and exhibited increased procoagulant activity in response to VEGF. Flt-1, flt-4 and KDR were detected in both freshly isolated endothelial cells, and in sparse and confluent endothelial cell cultures by RT-PCR. Attempts to modulate receptor expression by culturing cells at reduced oxygen tensions (2%) did not induce consistent changes in flt-1, flt-4 or KDR expression. Incubation with tumor-conditioned medium or co-culture of endothelial cells with a range of breast and small cell lung carcinoma cell lines did not reproducibly alter receptor mRNA expression. However, flt-1, flt-4 and KDR transcript levels were enhanced following treatment with tetradecanoylphorbol acetate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630024     DOI: 10.1006/bbrc.1996.0659

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Does telomerase reverse transcriptase induce functional de-differentiation of human endothelial cells?

Authors:  Yvonne Baumer; Dorothee Funk; Burkhard Schlosshauer
Journal:  Cell Mol Life Sci       Date:  2010-03-30       Impact factor: 9.261

2.  Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension.

Authors:  Ayser Al-Husseini; Donatas Kraskauskas; Eleanora Mezzaroma; Andrea Nordio; Daniela Farkas; Jennifer I Drake; Antonio Abbate; Quentin Felty; Norbert F Voelkel
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 3.  Mathematical modelling of angiogenesis.

Authors:  M A Chaplain
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Immunolocalisation of the VEGF receptors FLT-1, KDR, and FLT-4 in diabetic retinopathy.

Authors:  G Smith; D McLeod; D Foreman; M Boulton
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

5.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells.

Authors:  A Papapetropoulos; G García-Cardeña; J A Madri; W C Sessa
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.

Authors:  Z Y Liu; R K Ganju; J F Wang; M A Ona; W C Hatch; T Zheng; S Avraham; P Gill; J E Groopman
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

7.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia.

Authors:  B Witzenbichler; T Asahara; T Murohara; M Silver; I Spyridopoulos; M Magner; N Principe; M Kearney; J S Hu; J M Isner
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

8.  Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours.

Authors:  V Speirs; S L Atkin
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

9.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

Authors:  Y Ohta; V Shridhar; R K Bright; G P Kalemkerian; W Du; M Carbone; Y Watanabe; H I Pass
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

10.  VEGF receptor expression decreases during lung development in congenital diaphragmatic hernia induced by nitrofen.

Authors:  L Sbragia; A C C Nassr; F L L Gonçalves; A F Schmidt; C C Zuliani; P V Garcia; R M Gallindo; L A V Pereira
Journal:  Braz J Med Biol Res       Date:  2014-01-17       Impact factor: 2.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.